Literature DB >> 25684438

Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy.

Mira Keyes1, Tom Pickles2, Juanita Crook3, Michael McKenzie2, Arthur Cheung4, Ingrid Spadinger2, Vincent LaPointe2, W Francois Bachand3, James Morris2.   

Abstract

PURPOSE: To evaluate long-term erectile function (EF) in men treated with iodine-125 prostate brachytherapy (PB) and to determine factors predictive for erectile dysfunction (ED), including natural decline because of aging.
METHODS: Two thousand nine hundred twenty-nine patients (implanted July 1989-June 2012) with baseline EF and greater than 10-month followup (FU) are included. About 78.9% had full and 7.9% had partial EF at baseline. EF was assessed on a physician-reported three-point scale. Poisson regression with generalized estimating equations was used to assess predictors of ED and Kaplan-Meier curves time to ED. The effect of aging was calculated from the declining rate of baseline EF seen in sequential 5-year age cohorts and from the Massachusetts Male Aging Study.
RESULTS: The median age was 66 years and median FU 3.5 years (maximum 14 years). About 1142 patients had more than 5 years of FU, and 43% had received 6 months of androgen deprivation therapy (ADT). Significant drop in EF was seen at 6 weeks after PB, with gradual decline thereafter. EF preservation at 5 years for age younger than 55, 56-59, 60-64, 65-69, and 70 year and older was 82%, 73%, 58%, 39%, and 23%, respectively. Comparisons of the 5-year age-related and treatment-related EF decline show that 50% of the long-term EF decline is related to aging. On univariate and multivariate analyses, age at implant, length of FU, hypertension, diabetes, and use of ADT (all p < 0.01) were significant predictors of ED.
CONCLUSION: More than 80% of young men have EF preserved 5 years after PB. Age, ADT, history of hypertension, and the natural decline in EF have negative impact on long-term EF after PB. Crown
Copyright © 2015. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Erectile dysfunction; LDR prostate brachytherapy; Male aging; Predictive factors

Mesh:

Substances:

Year:  2015        PMID: 25684438     DOI: 10.1016/j.brachy.2015.01.001

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  3 in total

Review 1.  Radiation-induced erectile dysfunction: Recent advances and future directions.

Authors:  Javed Mahmood; Aksinija A Shamah; T Michael Creed; Radmila Pavlovic; Hotaka Matsui; Masaki Kimura; Jason Molitoris; Hem Shukla; Isabel Jackson; Zeljko Vujaskovic
Journal:  Adv Radiat Oncol       Date:  2016-06-03

2.  Toxicity in patients treated with permanent prostate brachytherapy using intraoperatively built custom-linked seeds versus loose seeds.

Authors:  Luc Ollivier; Francois Lucia; Truongan Nguyen; Caroline Lucas; Vincent Bourbonne; Nicolas Boussion; Gaelle Goasduff; Georges Fournier; Olivier Pradier; Gurvan Dissaux; Antoine Valeri; Ulrike Schick
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

3.  Low-dose-rate brachytherapy as a minimally invasive curative treatment for localised prostate cancer has excellent oncological and functional outcomes: a retrospective analysis from a single centre.

Authors:  Pieter D'hulst; Pieter Mattelaer; Jochen Darras; Lorenzo Staelens; Hans Pottel; Diederik Ponette
Journal:  Cent European J Urol       Date:  2018-09-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.